selpercatinib
Market Access/ News/ News/ News/ Oncology
Lilly keeps ahead of Blueprint with swift FDA review for selpercatinib
Phil Taylor
Blueprint Medicines, Eli Lilly, Loxo Oncology, novel targeted cancer treatments, Oncology, RET inhibitor, selpercatinib
0 Comment
X
Lilly keeps ahead of Blueprint with swift FDA review for selpercatinib
https://pharmaphorum.com/news/lilly-keeps-ahead-of-blueprint-with-swift-fda-review-for-selpercatinib/
News/ News/ Oncology/ Top stories
Relief for Lilly as drug from $8bn Loxo deal clears pivotal trial
Phil Taylor
Eli Lilly, Loxo Oncology, lung cancer, Non-small cell lung cancer, novel targeted cancer treatments, Oncology, RET inhibitor, selpercatinib
0 Comment
X
Relief for Lilly as drug from $8bn Loxo deal clears pivotal trial
https://pharmaphorum.com/news/relief-for-lilly-as-drug-from-8bn-loxo-deal-clears-pivotal-trial/